Zoological research
Cure8 research brief
Why This Matters
This preclinical study identifies a novel peptide (spexin) and a biased signaling pathway (SPX–GALR2–Gq) that reduced colitis in mouse models, suggesting a new target and a designed peptide candidate for future IBD therapies.
Who Should Pay Attention
Researchers, drug developers, and clinicians following preclinical therapeutic advances for IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports preclinical lab and mouse-model experiments identifying spexin (SPX), a neuropeptide that acts on galanin receptor 2 (GALR2), as protective in mouse models of colitis.
The authors show SPX signals through a Gq-biased pathway at GALR2 to suppress inflammation and promote epithelial repair, and they describe a mutant peptide (SPX p.Lys11Leu) with higher GALR2 affinity that was more potent than wild-type SPX in their models.
The work is mechanistic and preclinical: it uses receptor knockout mice, intestinal-epithelial–specific genetic knockouts, receptor inhibitors, structure-guided mutagenesis, and peptide design to map the signaling pathway and test activity in colitis models.
This is early-stage research that nominates SPX and a mutated version as peptide drug candidates for IBD; it does not report human clinical data or safety in people.
Keep In Mind
Findings are mechanistic and limited to cell and mouse models; no human trial or clinical safety data are reported in this article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationZoological research
AuthorsXue JW, Zhang T, Kong XL +8 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor.
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling.
The study identifies thymosin β4 as a protective factor in experimental colitis and suggests an injectable/oral recombinant peptide might reduce inflammation and intestinal fibrosis by suppressing mineralocorticoid...
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
The work identifies an endogenous peptide (Tβ4) that is reduced in IBD and shows that replacing it in mice lessens colitis and intestinal fibrosis, pointing to a new potential treatment target for inflammation and...